U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Tue Apr 01 23:26:33 GMT 2025
Edited
by admin
on Tue Apr 01 23:26:33 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
RM16A4BA8R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OBEXELIMAB
USAN   INN  
Official Name English
XMAB-5871
Preferred Name English
XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Common Name English
OBEXELIMAB [USAN]
Common Name English
Obexelimab [WHO-DD]
Common Name English
XMAB5871
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB5871 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB5871 LIGHT CHAIN, DIMER
Systematic Name English
obexelimab [INN]
Common Name English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD19 (DIFFERENTIATION ANTIGEN CD19T-CELL SURFACE ANTIGEN LEU-12))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-451) (MUS MUSCULUS VH (IGHV1-14*01 (78%) (IGHD)-IGHJ4*01 (100%))
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 566516
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
Code System Code Type Description
USAN
FG-171
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
DRUG BANK
DB15032
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
SMS_ID
100000183087
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
INN
10898
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
FDA UNII
RM16A4BA8R
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
CAS
1958118-77-8
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
NO STRUCTURE GIVEN
CAS
1690307-05-1
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
NCI_THESAURUS
C170236
Created by admin on Tue Apr 01 23:26:33 GMT 2025 , Edited by admin on Tue Apr 01 23:26:33 GMT 2025
PRIMARY
From To
1_22 1_96
1_148 1_204
1_265 1_325
1_371 1_429
1_224 3_219
1_230 2_230
1_233 2_233
2_22 2_96
2_148 2_204
2_265 2_325
2_371 2_429
2_224 4_219
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_301
N 2_301
Related Record Type Details
B-LYMPHOCYTE ANTIGEN CD19
TARGET -> INHIBITOR
Co-ligation of CD19 and FcgRIIb leads to downregulation and inhibition of B lineage cells bearing these targets.
LOW AFFINITY IMMUNOGLOBULIN .GAMMA. FC REGION RECEPTOR II-B
TARGET -> AGONIST
Co-ligation of CD19 and FcgRIIb leads to downregulation and inhibition of B lineage cells bearing these targets.
BINDING
Related Record Type Details
OBEXELIMAB
ACTIVE MOIETY
immunomodulator
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966